Ramucirumab

A4DAB217 | Cancer | Approved
KDR/CD309/VEGFR2
G1 / IgG1
Dyax AstraZeneca Dana-Farber Cancer Institute Eli Lilly Merck Sharp & Dohme University of Texas M. D. Anderson Cancer Center Washington University School of Medicine
Approved
Whole mAb
Cyramza IMC-1121 IMC1121 IMC 1121 IMC-1C11 IMC1C11 IMC 1C11 LY-3009806 LY 3009806 LY3009806 Ramcilumab Ramsilmab Ramsilomab Ramsylmab Ramsylumab Sairamza Silamza
6
IMGT PubChem (131408697) PubChem (135285364) PubChem (160666631) PubChem (178103962) PubChem (347910183) PubChem (354355038) PubChem (384647101) PubChem (385327559) PubChem (387060193) PubChem (459140361) PubChem (469690935) PubChem (472264660) PubChem (472397511) PubChem (475546934) PubChem (476272603) PubChem (481101818) PubChem (481149735) PubChem (488293647) PubChem (496156069) PubChem (496740909) PubChem (505242573) PubChem (513253724) PubChem (519905010) Thera-SAbDab YAbS
Avg A4D Score
-0.635
Score Range
-0.65 to -0.62
Structures
3
Avg. A4D Score per Structure
pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2

Structure ID Source PDB Seq. Identity Avg. A4D Score pH (Min Agg.) pH (Max Agg.) Score CDR Score non-CDR
A4DAB217_3s34_H_L 3s34 100% -0.6323 6.5 4.0 -0.2989 -0.6696
A4DAB217_3s37_H_L 3s37 100% -0.6493 6.5 4.0 -0.2896 -0.6902
A4DAB217_3s36_H_L 3s36 100% -0.6234 6.5 4.0 -0.2834 -0.6614